Effect of macrophage-activating factor (GcMAF-RF) upon ex vivo polarization of macrophages, activation of dendritic cells and production of cytokines by human whole blood cells

This article is the second communication in a series of articles devoted to the effects of a domestic preparation of macrophage-activating factor (GcMAF-RF) and assessment of its biological properties. The aim of this work was to study the effect of the GcMAF-RF upon M0 → M1 polarization of macrophages (Mph), and activation of the professional properties of ex vivo generated antigen-presenting dendritic cells (DC), as well as on ex vivo production of pro-inflammatory (TNFα, IL-1β, IL-6, IFNγ, IL-17, IL-18) and anti-inflammatory (TGF-β, IL-4, IL-10) cytokines, growth factors (IL-2, GM-CSF, G-CSF, VEGF) and chemokines (MCP, IL-8) by the whole blood cells from healthy donors. Mph and DC were generated from the monocytes (3 to 5×106 /ml) derived from adherent fraction of peripheral blood mononuclear cells (MNC) of healthy donors. Granulocyte/macrophage colony-stimulating factor (rhGM-CSF) was used to obtain Mph, whereas DC production was induced by GM-CSF and interferon-α. To provide M1 polarizing signals, bacterial lipopolysaccharide (LPS from E. coli 0114:B4) was used in controls. In experimental series, GcMAF-RF was added 48 h before the end of culture. The stimulating effect of the obtained Mph and DC upon cell proliferation was assessed in allogeneic mixed culture of leukocytes (alloMLC) using radiometric technique, by 3 H-thymidine incorporation. The influence index (IR) of Mph or DC upon allo-SCL was calculated as the ratio of the proliferative response of MNCs in the presence of Mph, or DC to the level of spontaneous MNC proliferation. To determine the cytokine production by human whole blood cells ex vivo, peripheral blood samples from 3 donors with two replicate GcMAF-RF preparations were used, at a total of 6 points. All variants of the study were carried out with mitogen-activated and non-activated blood cells. The cytokine content was determined by the ELISA assays. The effects of GcMAF-RF were quantified as a fold increase (FI), i.e., the ratio of cytokine production in the presence of GcMAF-RF to the level of their spontaneous production. It was shown that the GcMAF-RF preparation was as effective, as lipopolysaccharide (LPS), the standard Mph and DC activator which induces polarization of differentiated M0-macrophages into M1 cells and final maturation of DCs, manifesting by a significant increase in their allo-stimulatory activity in a mixed leukocyte culture (allo-MLC). Moreover, GcMAF-RF stimulates production of numerous cytokines and chemokines (TNFα, IL-1β, IL-6, IL-18, IL-4, IL-10, GM-CSF, G-CSF, VEGF, IL-8), by blood cells (granulocytes, lymphocytes, monocytes), thus indicating direct participation of the macrophage activator GcMAF-RF in various immune processes. The domestic GcMAF-RF drug induces polarization of macrophages M0 → M1, final maturation of DCs and allostimulating activity of Mf and DCs, and is also able to effectively stimulate circulating blood cells to synthesize cytokines/chemokines with pro-inflammatory and immunoregulatory activities. 

1. Ketlinsky S.A., Simbirtsev A.S. Cytokines. St. Petersburg: Foliant, 2008. 552 p.

2. Kozlova A.I., Voropaev E.V., Konoplya A.I. The role of dendritic cells in the formation of antitumor immunity (literature review). Problemy zdorovya i ekologii = Health and Ecology Problems, 2015, pp. 19-24. (In Russ.)

3. Levites E.V., Kirikovich S.S., Dolgova E.V., Proskurina A.S., Ritter G.S., Ostanin A.A., Chernykh E.R., Bogachev S.S. In vitro assay of biological activity of a national preparation of macrophage activating factor (GcMAF-RF). Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Breeding, 2020, Vol. 24, no. 3, pp. 284-291. (In Russ.)

4. Leplina O.Yu., Tikhonova M.A., Kozlov Yu.P., Stupak V.V., Nikonov S.D., Ostanin A.A., Chernykh E.R. Semimature dendritic cells as a potential basis for the induction of anti-tumor response in patients with malignant gliomas. Meditsinskaya immunologiya = Medical Immunology (Russia), 2005, Vol. 7, no. 4, pp. 365-374. (In Russ.) doi: 10.15789/1563-0625-2005-4-365-374.

5. Leplina O.Yu., Tikhonova M.A., Tyrinova T.V., Alyamkina E.A., Bogachev S.S., Ostanin A.A., Chernykh E.R. Functional activity of IFNα- and IL-4- induced human dendritic cells: a comparative study. Meditsinskaya immunologiya = Medical Immunology (Russia), 2014, Vol. 16, no. 1, pp. 43-52. (In Russ.) doi: 10.15789/1563-0625-2014-1-43-52.

6. Monastyrskaya E.A., Lyamina S.V., Malyshev I.Yu. M1 and M2 phenotypes of activated macrophages and their role in the immune response and pathology. Patogenez = Pathogenesis, 2008, Vol. 6, no. 4, pp. 31-39. (In Russ.)

7. Ostanin A.A., Kirikovich S.S., Dolgova E.V., Proskurina A.S., Chernykh E.R., Bogachev S.S. A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Breeding, 2019, Vol. 23, no. 5, pp. 624-631. (In Russ.)

8. Ryzhikova S.L., Druzhinina Yu.G., Ryabicheva T.G., Varaksin N.A. Standardization of the method for determining the production of cytokines by blood cells ex vivo. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2011, Vol. 11, pp. 49-53. (In Russ.)

9. Sakhno I.V., Shevela E.Ya., Tikhonova M.A., Ostanin A.A., Chernykh E.R. Molecular mechanisms of M2 macrophage immunosuppressive activity. Immunologiya = Immunologiya, 2016, Vol. 37, no. 6, pp. 311-315. (In Russ.)

10. Talaev V.Yu., Plekhanova M.V., Matveichev A.V. Experimental models suitable for evaluating the effect of components of new vaccines under development on dendritic cell differentiation. Medial, 2014, Vol. 2, no. 12, pp. 135-153. (In Russ.)

11. Chernykh E.R., Leplina O.Yu., Tyrinova T.V., Tikhonova M.A., Stupak V.V., Mishinov S.V., Pendyurin I.V., Ostanin A.A. Anti-tumor activity of dendritic cells in healthy donors and patients with brain tumors. Meditsinskaya immunologiya = Medical Immunology (Russia), 2010, Vol. 12, no. 3, pp. 199-206. (In Russ.)

12. Chernykh E.R., Tyrinova T.V., Leplina O.Yu., Tikhonova M.A., Kurochkina Yu.D., Oleynik E.A., Sakhno L.V., Ostanin A.A. Phenotype and functions of human dendritic cells derived from CD14+ monocyte subsets opposed to CD16 expression. Byulleten sibirskoy meditsiny = Bulletin of Siberian Medicine, 2019, Vol. 18, no. 1, pp. 266-276. (In Russ.)

13. Shevela E.Ya., Yankovskaya A.A., Sakhno L.V., Ostanin A.A., Chernykh E.R. Pat. RF 2717024 Method for identification of functional M1 and M2 phenotype of human macrophages generated in vitro from blood monocytes / No. 2019118746, Appl. 06/17/2019; publ. 03.17.2020, Bul. No. 8.

14. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature, 1998, Vol. 392, no. 6673, pp. 245-252.

15. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev., 2008, Vol. 19, no. 1, pp. 41-52.

16. Cassetta L., Cassol E., Poli G. Macrophage polarization in health and disease. Sci. World J., 2011, Vol. 11, pp. 2391-2402.

17. Cheda A., Nowosielska E.M., Wrembel-Wargocka J., Janiak M.K. Production of cytokines by peritoneal macrophages and splenocytes after exposures of mice to low doses of X-rays. Radiat. Environ. Biophys., 2008, Vol. 47, pp. 275-283.

18. Duque G.A., Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol., 2014, Vol. 5, 491. doi: 10.3389/fimmu.2014.00491.

19. Fleetwood A.J., Lawrence T., Hamilton J.A., Cook A.D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol., 2007, Vol. 178, no. 8, pp. 5245-5252.

20. Fogg D.K., Sibon C., Miled C., Jung S., Aucouturier P., Littman D.R., Cumano A., Geissmann F.A. Clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science, 2006, Vol. 311, no. 5757, pp. 83-87.

21. Geissmann F., Gordon S., Hume D.A., Mowat A.M., Randolph G.J. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol., 2010, Vol. 10, no. 6, pp. 453-460.

22. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol., 2003, Vol. 3, pp. 23-35.

23. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol., 2005, Vol. 5, no. 12, pp. 953-964.

24. Homma S., Yamamoto M., Yamamoto N. Vitamin D-binding protein (group-specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol. Cell Biol., 1993, Vol. 71, pp. 249-257.

25. Hume D.A. Macrophages as APC and the dendritic cell myth. J. Immunol., 2008, Vol. 181, no. 9, pp. 5829-5835.

26. Inui T., Kuchiike D., Kubo K., Mette M., Uto Y., Hori H., Sakamoto N. Clinical experience of integrative cancer immunotherapy with GcMAF. Anticancer Res., 2013, Vol. 33, no. 7, pp. 2917-2919.

27. Ishikawa M., Inoue T., Inui T., Kuchiike D., Kubo K., Uto Y., Nishikata T. A novel assay system for macrophageactivating factor activity using a human U937 cell line. Anticancer Res., 2014, Vol. 34, no. 8, pp. 4577-4581.

28. Jaguin M., Houlbert N., Fardel O., Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell. Immunol., 2013, Vol. 281, pp. 51-61.

29. Kisker O., Onizuka S., Becker C.M., Fannon M., Flynn E., d’Amato R., Zetter B., Folkman J., Ray R., Swamy N., Pirie-Shepherd S. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia, 2003, Vol. 5, no. 1, pp. 32-40.

30. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 2013, Vol. 31, pp. 51-72.

31. Kuchiike D., Uto Y., Mukai H., Ishiyama N., Abe C., Tanaka D., Kawai T., Kubo K., Mette M., Inui T., Endo Y., Hori H. Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity. Anticancer Res., 2013, Vol. 33, no. 7, pp. 2881-2885.

32. Kurosaka K., Takahashi M., Kobayashi Y. Activation of extracellular signal-regulated kinase 1/2 is involved in production of CXC-chemokine by macrophages during phagocytosis of late apoptotic cells. Biochem. Biophys. Res. Commun., 2003, Vol. 306, no. 4, pp. 1070-1074.

33. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol., 2006, Vol. 80, no. 4, pp. 705-713.

34. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci., 2008, Vol. 1, no. 13, pp. 453-461.

35. Mohamad S.B., Nagasawa H., Uto Y., Hori H. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2002, Vol. 132, pp. 1-8.

36. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol., 2011, Vol. 11, no. 11, pp. 723-737.

37. Nagasawa H., Uto Y., Sasaki H., Okamura N., Murakami A., Kubo S., Kirk K.L., Hori H. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res., 2005, Vol. 25, no. 6, pp. 3689-3696.

38. Nagy L., Szanto A., Szatmari I., Szeles, L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol. Rev., 2012, Vol. 92, pp. 739-789.

39. Naraparaju V.R., Yamamoto N. Roles of β-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol. Lett., 1994, Vol. 43, no. 3, pp. 143-148.

40. O’Shea J.J., Siegel R.M. Cytokines and cytokine receptors. Clinical immunology. Ed. Rich R.R., Fleisher T.A., Shearer W.T., Schroeder H.W., Frew A.J., Weyand C.M. Elsevier, 2019, pp. 127-155.

41. Rehder D.S., Nelson R.W., Borges C.R. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci., 2009, Vol. 18, no. 10, pp. 2036-2042.

42. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm., 2015, Vol. 2015, 816460. doi: 10.1155/2015/816460.

43. Saburi E., Saburi A., Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Casp. J. Intern. Med., 2017, Vol. 8, no. 4, pp. 228-238.

44. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest., 2007, Vol. 117, no. 5, pp. 1155-1166.

45. Tarique A.A., Logan J., Thomas E., Holt P.G., Sly P.D., Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am. J. Respir. Cell Mol. Biol., 2015, Vol. 53, no. 5, pp. 676-688.

46. Thyer L., Ward E., Smith R., Branca J.J.V., Morucci G., Gulisano M., Noakes D., Eslinger R., Pacini S. GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology, 2013, Vol. 2, no. 8, pp. 1-7.

47. Thyer L., Ward E., Smith R., Fiore M., Magherini S., Branca J., Morucci G., Gulisano M., Ruggiero M., Pacini S. A novel role for a major component of the vitamin d axis: vitamin d binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients, 2013, Vol. 5, no. 7, pp. 2577-2589.

48. Weagel E., Smith C., Liu P., Robinson R., O’Neill K. Macrophage polarization and its role in cancer. J. Clin. Cell Immunol., 2015, Vol. 6, pp. 4-11.

49. Yamamoto N., Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc. Natl. Acad. Sci., 1991, Vol. 88, no. 19, pp. 8539-8543.

50. Yamamoto N., Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J. Immunol., 1993, Vol. 151, no. 5, pp. 2794-2802.

51. Yamamoto N., Naraparaju V.R., Asbell S.O. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res., 1996, Vol. 56, no. 12, pp. 2827-2831.

52. Yamamoto N., Suyama H., Yamamoto N. Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl. Oncol., 2008, Vol. 1, pp. 65-72.

53. Yaraee R., Askari N., Naseri M. The effect of ms14 on production of pro-inflammatory cytokines by macrophages. Iran. J. Basic Med. Sci., 2011. Vol. 14, no. 1, pp. 89-93.

54. Zhang G.-M., Wang X.-H., Sun L.-J. Effect of tacrolimus on maturity and allostimulatory activity of cultured dendritic cells of rats in vitro. Chinese Journal of Pharmacology and Toxicology, 2009, Vol. 23, no. 5, pp. 345-350.

55. Zhou F., Zhang G-X., Rostami A. Distinct role of IL-27 in immature and LPS-induced mature dendritic cell-mediated development of CD4+CD127+3G11+ regulatory T cell subset. Front. Immunol., 2018, Vol. 9, 2562. doi 10.3389/fimmu.2018.02562.